联用细菌溶解产物治疗咳嗽变异性哮喘的临床评价
Clinical Evaluation of the Treatment of Cough Variant Asthma with Bacterial Solubilization Products
DOI: 10.12677/acm.2025.1572044, PDF,   
作者: 杜雨鸽：西安医学院研究生处，陕西 西安；吴 桦*：陕西省人民医院呼吸与危重症科，陕西 西安
关键词: 咳嗽变异性哮喘；细菌溶解产物；临床治疗；预防及治疗效果；Cough Variability Asthma； Bacterial Dissolved Products； Clinical Treatment； Prevention and Treatment Effects
摘要: 咳嗽变异型哮喘是我国慢性咳嗽的主要病因之一，且容易发展为典型哮喘，进而加重患者的经济负担及痛苦。细菌溶解产物是一种免疫调节药物，主要应用于呼吸道疾病的治疗及预防且疗效显著，不仅缩短了疾病治愈时间，而且可以提高患者免疫力，从而减少疾病的发生。但该药物在临床中并未常规使用，考虑与目前临床研究较少，许多医师对于其在临床治疗中的疗效不确定性相关。所以本文将对细菌溶解产物这一药物用于治疗CVA的研究评价、不良反应进行综述，为广大临床医生对于CVA的治疗方案提供参考，减轻患者痛苦。
Abstract: Cough variant asthma is one of the main causes of chronic cough in China, and it is easy to develop into typical asthma, which increases the financial burden and suffering of patients. Bacterial lysate is a kind of immunomodulatory drug, which is mainly used in the treatment and prevention of respiratory tract disease. It can not only shorten the curing period of the disease, but also improve the immune system and reduce the incidence of disease. However, the drug is not routinely used in the clinic, considering that there are currently few clinical studies and many physicians have uncertainty about its efficacy in clinical treatment. Therefore, this article will review the research evaluation and adverse reactions of bacterial dissolved product as a drug for the treatment of CVA, to provide information for the general clinician on the treatment plan for CVA and to alleviate the suffering of patients.
文章引用：杜雨鸽, 吴桦. 联用细菌溶解产物治疗咳嗽变异性哮喘的临床评价[J]. 临床医学进展, 2025, 15(7): 709-715. https://doi.org/10.12677/acm.2025.1572044

参考文献

[1] Hu, Y., Zheng, S., Chen, Z., Yu, D., Lai, T., Chen, Y., et al. (2023) Validity of Fractional Exhaled Nitric Oxide and Small Airway Lung Function Measured by IOS in the Diagnosis of Cough Variant Asthma in Preschool Children with Chronic Cough. Allergy, Asthma & Clinical Immunology, 19, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[2] 邱忠民. 咳嗽变异性哮喘的诊治进展[J]. 赣南医学院学报, 2021, 41(8): 797-800, 807.
[3] Chen, J., Lin, W., Gu, H., Ying, K., Li, T. and Shao, H. (2022) Study on the Relationship between Bronchoalveolar Lavage Fluid Cell Count, Th1/Th2 Cytokines and Pulmonary Function in Patients with Cough Variant Asthma. Journal of Asthma and Allergy, 15, 1713-1720. [Google Scholar] [CrossRef] [PubMed]
[4] 陈婷婷, 易桂生. 咳嗽变异性哮喘病理机制及造模方法的研究进展[J]. 实验动物科学, 2021, 38(2): 74-78.
[5] Feddema, J.J. and Claassen, E. (2020) Prevalence of Viral Respiratory Infections Amongst Asthmatics: Results of a Meta-Regression Analysis. Respiratory Medicine, 173, Article ID: 106020. [Google Scholar] [CrossRef] [PubMed]
[6] Diab, N., Patel, M., O’Byrne, P. and Satia, I. (2022) Narrative Review of the Mechanisms and Treatment of Cough in Asthma, Cough Variant Asthma, and Non-Asthmatic Eosinophilic Bronchitis. Lung, 200, 707-716. [Google Scholar] [CrossRef] [PubMed]
[7] Huang, H.Q., Hua, W., Chen, R.C., et al. (2021) Perspectives and Management of Atypical Asthma in Chinese Specialists and Primary Care Practitioners-A Nationwide Questionnaire Survey. Frontiers in Medicine, 8, Article 727381.
[8] 赵艳楠, 赵琦. 细菌溶解产物胶囊联合异丙托溴铵雾化吸入对支气管哮喘患者临床疗效的影响[J]. 现代医学与健康研究电子杂志, 2022, 6(14): 52-54.
[9] de Boer, G.M., Żółkiewicz, J., Strzelec, K.P., Ruszczyński, M., Hendriks, R.W., Braunstahl, G., et al. (2020) Bacterial Lysate Therapy for the Prevention of Wheezing Episodes and Asthma Exacerbations: A Systematic Review and Meta-Analysis. European Respiratory Review, 29, Article ID: 190175. [Google Scholar] [CrossRef] [PubMed]
[10] 徐英, 王晶莉, 尹虹雷, 等. 探讨呼出气一氧化氮测定联合痰细胞计数评估哮喘表型[J]. 中国继续医学教育, 2021, 13(10): 121-124.
[11] 张亚丽, 蒋毅, 安若丽, 等. 不同临床表型哮喘患者咳嗽和气道炎症特点分析[J]. 临床肺科杂志, 2023, 28(11): 1677-1681.
[12] 别柏林, 李安琪, 楚荷莹. FeNO联合血清SDF-1水平对支气管哮喘患者气道高反应的预测价值[J]. 临床肺科杂志, 2021, 26(10): 1506-1510.
[13] 丁金盾, 邱章伟, 徐晓婷, 等. 呼出气一氧化氮与小气道功能预测咳嗽变异性哮喘患者支气管高反应性[J]. 临床肺科杂志, 2022, 27(2): 169-173, 183.
[14] Bai, H., Shi, C., Yu, S., Wen, S., Sha, B., Xu, X., et al. (2023) A Comparative Study on the Value of Lower Airway Exhaled Nitric Oxide Combined with Small Airway Parameters for Diagnosing Cough-Variant Asthma. Therapeutic Advances in Respiratory Disease, 17, 1-11. [Google Scholar] [CrossRef] [PubMed]
[15] 张雯婧, 代向东, 刘帅, 等. 气道高反应性疾病动物模型研究进展[J]. 天津中医药大学学报, 2023, 42(5): 643-649.
[16] Poto, R., Shamji, M., Marone, G., Durham, S.R., Scadding, G.W. and Varricchi, G. (2022) Neutrophil Extracellular Traps in Asthma: Friends or Foes? Cells, 11, Article 3521. [Google Scholar] [CrossRef] [PubMed]
[17] Yi, F., Jiang, Z., Li, H., Guo, C., Lu, H., Luo, W., et al. (2022) Small Airway Dysfunction in Cough Variant Asthma: Prevalence, Clinical, and Pathophysiological Features. Frontiers in Physiology, 12, Article 761622. [Google Scholar] [CrossRef] [PubMed]
[18] 王忠照, 唐昊. 哮喘的气道重构机制研究进展[J]. 结核与肺部疾病杂志, 2023, 4(2): 158-163.
[19] 仲彩铭. IDO1调控的色氨酸代谢在过敏性哮喘气道重构中的机制研究[D]: [硕士学位论文]. 重庆: 中国人民解放军海军军医大学, 2023.
[20] 张玉, 布拉力·热西提, 许珺, 等. 血清IL-10、IL-22水平对老年重症支气管哮喘患者气道重构程度预测价值[J]. 疑难病杂志, 2021, 20(12): 1197-1200.
[21] 屈乐言, 罗建江, 张多兰, 等. 支气管哮喘患儿外周血suPAR、JAK/STAT信号通路与气道重构的相关性分析[J]. 疑难病杂志, 2024, 23(2): 160-164.
[22] Rossi, G.A., Pohunek, P., Feleszko, W., Ballarini, S. and Colin, A.A. (2020) Viral Infections and Wheezing-Asthma Inception in Childhood: Is There a Role for Immunomodulation by Oral Bacterial Lysates? Clinical and Translational Allergy, 10, Article No. 17. [Google Scholar] [CrossRef] [PubMed]
[23] Fu, R., Li, J., Zhong, H., Yu, D., Zeng, X., Deng, M., et al. (2014) Broncho-Vaxom Attenuates Allergic Airway Inflammation by Restoring GSK3β-Related T Regulatory Cell Insufficiency. PLOS ONE, 9, e92912. [Google Scholar] [CrossRef] [PubMed]
[24] Esposito, S., Jones, M.H., Feleszko, W., Martell, J.A.O., Falup-Pecurariu, O., Geppe, N., et al. (2020) Prevention of New Respiratory Episodes in Children with Recurrent Respiratory Infections: An Expert Consensus Statement from the World Association of Infectious Diseases and Immunological Disorders (WAIDID). Microorganisms, 8, Article 1810. [Google Scholar] [CrossRef] [PubMed]
[25] 李静, 张胜男. 丙酸氟替卡松联合细菌溶解产物治疗咳嗽变异性哮喘的临床效果观察[J]. 今日药学, 2022, 32(11): 859-862.
[26] 齐莎莎, 张国伟, 孟凡威, 等. 细菌溶解产物胶囊联合扎鲁司特、布地奈德气雾剂治疗支气管哮喘缓解期患儿的效果观察[J]. 医学理论与实践, 2022, 35(23): 4057-4059.
[27] 靳倩, 李淑芳. 细菌溶解产物胶囊辅助治疗支气管哮喘急性发作期患儿的效果[J]. 河南医学研究, 2021, 30(28): 5322-5325.
[28] 侯杰. 细菌溶解产物胶囊联合常规药物治疗小儿支气管哮喘急性发作的临床效果[J]. 临床医学研究与实践, 2019, 4(27): 91-92.
[29] 蔡为为, 王东亮. 细菌溶解产物胶囊联合沙美特罗替卡松治疗对哮喘患者血清炎症介质的影响[J]. 中国药物经济学, 2019, 14(11): 56-58, 62.
[30] 黎鸣桃, 黄淑芹, 张可妃, 等. 细菌溶解产物胶囊联合布地奈德雾化吸入治疗对咳嗽变异性哮喘患儿免疫功能、气道功能的影响[J]. 临床和实验医学杂志, 2023, 22(2): 175-179.
[31] 王和庆. 细菌溶解产物胶囊联合布地奈德混悬液、特布他林治疗支气管哮喘急性发作患者的效果[J]. 中国民康医学, 2022, 34(7): 11-14.
[32] 吴晓旭. 泛福舒联合丙酸倍氯米松雾化吸入治疗支气管哮喘急性发作期患儿的效果[J]. 中国医药导报, 2020, 17(3): 102-105.
[33] 王平晟. 沙丁胺醇雾化联合细菌溶解产物胶囊治疗支气管哮喘患儿的疗效分析[J]. 医学理论与实践, 2021, 34(13): 2205-2207, 2197.
[34] 王鑫. 细菌溶解产物辅助治疗支气管哮喘并发急性呼吸道感染患儿的效果[J]. 中国民康医学, 2022, 34(7): 65-67.
[35] 杨丽炜, 张亚丽, 刘霞, 等. 免疫调节剂辅助治疗儿童支气管哮喘急性发作效果及对免疫功能、血清嗜酸粒细胞阳离子蛋白、呼出气一氧化氮影响[J]. 临床误诊误治, 2020, 33(2): 26-31.
[36] de Boer, G.M., Braunstahl, G., van der Ploeg, E.K., van Zelst, C.M., van Bruggen, A., Epping, G., et al. (2021) Bacterial Lysate Add‐On Therapy to Reduce Exacerbations in Severe Asthma: A Double‐Blind Placebo‐Controlled Trial. Clinical & Experimental Allergy, 51, 1172-1184. [Google Scholar] [CrossRef] [PubMed]
[37] 蔡杰荣, 林正伦, 王登峰, 等. 细菌溶解产物胶囊对哮喘预测指数阳性患儿免疫功能及喘息控制水平的影响[J]. 临床肺科杂志, 2020, 25(1): 74-77.
[38] 杨芬, 华丽, 刘海沛, 等. 细菌溶解产物预防支气管哮喘儿童并发呼吸道感染的临床疗效观察[J]. 临床和实验医学杂志, 2020, 19(2): 158-161.
[39] 尹莉莉, 李伟, 殷爱云, 等. 孟鲁司特钠联合细菌溶解产物对哮喘患儿IL-33、s ST2受体、EOS、ECP的影响[J]. 中华肺部疾病杂志(电子版), 2021, 14(6): 803-805.
[40] 冯素枝, 苏兆贤. 布地奈德雾化吸入联合泛福舒治疗支气管哮喘急性发作的疗效及安全性分析[J]. 中国实用医药, 2020, 15(15): 109-111.
[41] 林木土, 王巧红, 许宝花. 细菌溶解产物胶囊联合常规药物治疗小儿支气管哮喘急性发作的临床效果[J]. 医学理论与实践, 2023, 36(5): 827-829, 812.

为你推荐